In Other News

• Phase 3 Clinical Trials of Monoclonal Antibodies to Prevent COVID-19 Begin Enrolling Adults at Risk of Infection

• Only Dual Anti-Inflammatory/Antiviral Medication in Development to Treat COVID-19 Shows Promise in Study

• Pre-Existing Immune Cell Memory That Recognizes Common Cold Coronaviruses Could Also Recognize and Fight off SARS-CoV-2

• Phase 1/2 Study of Self-Replicating mRNA-Based COVID-19 Vaccine Completes Dosing

• Gilead Seeks Full US FDA Approval for Experimental Coronavirus Drug Remdesivir for Treatment of COVID-19

• Korean Biopharmaceutical Firm Celltrion Launches Both Antigen and Antibody Testing Kits in the US

• China’s CanSino Biologics Begins Final Phase of Human Trials of COVID-19 Vaccine in Saudi Arabia

• World’s First COVID-19 Vaccine Launched by Russia Ahead of Completion of Final Testing

• New Recombinant Hyperimmune Drug Class Offers 100-Fold Higher Potency than Convalescent Serum Therapy for COVID-19

• New COVID-19 Mobile Testing Device Diagnoses Infection Immediately via Breath Sample Using AI

• Oral COVID-19 Vaccine Could Activate both Systemic and Mucosal Immunity for Protection against Coronavirus

• Thermo Fisher Develops New COVID-19 Antibody Assay Targeting Transplant Community

• Helix COVID-19 NGS Test One of the First Sequencing-Based COVID-19 Tests To Secure FDA Emergency Use Authorization

• AI Technology Detects Deterioration in COVID-19 Patients by Identifying Predictive Patterns in Their Vital Signs

• Newly-Engineered Antiviral Compounds Can Neutralize SARS-CoV-2 in Human Airway Cells

• Newly-Developed Enzyme Could Treat Mysterious Multisystem Complications of COVID-19

• BioMérieux SARS-CoV-2 Serology Tests Granted FDA Emergency Use Authorization

• NIH Begins Clinical Trial of Antiviral Remdesivir Plus Immunomodulator Interferon Beta-1a in COVID-19 Patients

• Pfizer Enters Into Multi-Year Agreement with Gilead to Manufacture Investigational Antiviral Remdesivir for COVID-19

• AstraZeneca Signs Licensing Deal with China’s BioKangtai for 100 Million Doses of Oxford COVID-19 Vaccine by Year End

• Human Trial of Pill That Could Reduce COVID-19 Related Lung Damage Begins At First US Clinical Trial Site

• No 'Silver Bullet' for COVID-19, Widespread Vaccine Distribution Unlikely To Occur For Some Time, Says WHO

• Antibodies Disappear in 10% of Coronavirus-Recovered Patients and 5% Test Positive Again In New Study